Adherence to and appropriateness of anti-osteoporotic treatments in patients aged 50 and over in the Valencia Region (Spain). the ESOSVAL-AD study

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Sanfélix Gimeno, Gabriel ^a   Sanfélix Genovés, José ^a,b   Peirá, Salvador ^a   Hurtado, Isabel ^a   Trillo, José ^c   Usá, Ruth ^c   Ruiz, Vicente ^d   De La Torre, Manuel ^e   Ferreros, Inmaculada ^a  

^a Centro Superior de Investigacián en Salud Pública Center for Public Health Research   (Spain)

^b Centro de Salud Nazaret   (Spain)

^c Direccián General de Farmacia y Productos Sanitarios   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^e Oficina de Abucasis   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOSTEOPOROSIS DRUG; BONE DENSITY CONSERVATION AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTEOPOROSIS; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY HEALTH CARE; PROSPECTIVE STUDY; SPAIN;

EID: 79961002530     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-178     Document Type: Article

References (24)

1. Excess mortality following hip fracture: a systematic epidemiological review. Abrahamsen B, van Staa T, Ariely R, Olson M, Cooper C, Osteoporos Int 2009 20 10 1633 50 10.1007/s00198-009-0920-3 19421703
2. The components of excess mortality after hip fracture. Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK, Bone 2003 32 5 468 73 10.1016/S8756-3282(03)00061-9 12753862 (Pubitemid 39665705)
3. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. Ioannidis G, Papaioannou A, Hopman WM, Akhtar-Danesh N, Anastassiades T, Pickard L, Kennedy CC, Prior JC, Olszynski WP, Davison KS, Goltzman D, Thabane L, Gafni A, Papadimitropoulos EA, Brown JP, Josse RG, Hanley DA, Adachi JD, CMAJ 2009 181 5 265 71 10.1503/cmaj.081720 19654194
4. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. Bliuc D, Nguyen ND, Milch VE, Nguyen TV, Eisman JA, Center JR, JAMA 2009 301 513 21 10.1001/jama.2009.50 19190316
5. [Osteoporotic fractures: risk assessment in clinical practice]. Vázquez Díaz M, Lápez García Franco A, Isasi Zaragozá C, Aguado Acín P, Med Clin (Barc) 2007 29 418 23
6. FRAX and the assessment of fracture probability in men and women from the UK. K Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E, Osteoporos Int 2008 19 385 97 10.1007/s00198-007-0543-5 18292978
7. National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Dawson-Hughes B, Tosteson AN, Melton LJ, Baim S, Favus MJ, Khosla S, Lindsay RL, Osteoporos Int 2008 19 449 4 10.1007/s00198-008-0559-5 18292975
8. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. Hippisley-Cox J, Coupland C, BMJ 2009 339 4229 10.1136/bmj.b4229 19926696
9. [Clinical characteristics of patients under treatment for osteoporosis in a Primary Care Centre. Who do we treat?]. De Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T, Aten Primaria 2010 42 11 559 63 10.1016/j.aprim.2009.10.022 20129712
10. Assuring the quality of questionnaire data in epidemiologic research. Gordis L, Am J Epidemiol 1979 109 1 21 4 433912
11. How to detect and manage low patient compliance in chronic illness. Haynes RB, Sackett DL, Taylor DW, Geriatrics 1980 35 1 91 3 96-7 7350072
12. Patient compliance and the conduct and interpretation of therapeutic trials. Haynes RB, Dantes R, Control Clin Trials 1987 8 1 12 9 10.1016/0197-2456(87)90021-3 3568692 (Pubitemid 17040574)
13. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Kripalan S, Yao X, Haynes RB, Arch Internal Med 2007 167 6 540 50 10.1001/archinte.167.6.540 (Pubitemid 46513223)
14. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate JM, Osteoporos Int 2010 21 11 1943 51 10.1007/s00198-009-1134-4 19967338
15. Determinant factors of osteoporosis patients' reported therapeutic adherence to calcium and/or vitamin D supplements: a cross-sectional, observational study of postmenopausal women. Sanfelix-Genovés J, Gil-Guillén VF, Orozco-Beltran D, Giner-Ruiz V, Pertusa-Martínez S, Reig-Moya B, Carratalá C, Drugs Aging 2009 26 10 861 9 10.2165/11317070-000000000-00000 19761279
16. Cumplimiento del tratamiento hormonal sustitutivo en mujeres menopáusicas. Pereirá Berenguera I, Sanfélix-Genovés J, García Cervera J, Furiá Bonet S, Vicente Polo JM, Martínez-Mir I, Med Clin (Barc) 2001 117 207 210
17. Drug therapy: patient compliance. Blackwell B, N Engl J Med 1973 289 5 249 52 10.1056/NEJM197308022890506 4713764
18. Development and validation of a population based prediction scale for osteoporotic fracture in the region of Valencia, Spain: the ESOSVAL-R study. Sanfélix-Genovés J, Peirá S, Sanfélix-Gimeno G, Giner V, Gil V, Pascual M, Fluixá C, Fuertes A, Hurtado I, Ferreros I, BMC Public Health 2010 10 153 10.1186/1471-2458-10-153 20334639
19. Medication compliance and persistence: terminology and definitions. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK, Value Health 2008 11 1 44 7 10.1111/j.1524-4733.2007.00213.x 18237359 (Pubitemid 351160875)
20. Guía de Práctica Clínica sobre Osteoporosis y Prevencián de Fracturas por Fragilidad. Grupo de trabajo de la Guía de Práctica Clínica sobre Osteoporosis y Prevencián de Fracturas por Fragilidad, Plan de Calidad para el Sistema Nacional de Salud del Ministerio de Sanidad, Política Social e Igualdad, Agència d'Informaciá, Avaluaciá, I Qualitat en Salut (AIAQS) de Catalũa; 2010 Guías de Práctica Clínica en el SNS: AATRM N° 2007/02
21. Osteoporosis, Semergen Doc. Avizanda M, Carbonell C, Casado P, Fernández C, Gámez F, Iglesias A, Ortega A, González M, Redondo E, Saavedra J, Valdés C, Edicomplet, Madrid- Barcelona, Pérez D, Santiago AM, 2007
22. Direccián General de Farmacia y Productos Sanitarios. Recomendaciones para la valoracián y tratamiento de la osteoporosis primaria en mujeres de la Comunidad, de Madrid Madrid: Comunidad de Madrid, Consejería de Sanidad 2007
23. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis Washington, DC: National Osteoporosis Foundation 2010 21818700
24. European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, Rizzoli R, Osteoporos Int 2008 19 4 399 428 10.1007/s00198-008-0560-z 18266020